Evaluation of Adefovir PBPK Model to Assess Biomarker‐Informed OAT1 Drug–Drug Interaction and Effect of Chronic Kidney Disease
CPT: Pharmacometrics & Systems Pharmacology · 2025-05 · 14 (5) · 964-974
DOI: 10.1002/psp4.70010 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 03.03.2025. Verfasst von Shawn Pei Feng Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Adenine, Organic Anion Transport Protein 1, Models, Biological, Organophosphonates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Evaluation of transporter‐mediated drug–drug interactions (DDI) with endogenous biomarkers, coupled with physiologically‐based pharmacokinetic modeling (PBPK) is envisioned to replace or reduce dedicated DDI clinical trials with clinical probe substrates. The current study developed a PBPK model of adefovir (OAT1 clinical probe) by incorporating experimental measurements of adefovir passive diffusion and OAT1‐mediated transport in a mechanistic kidney model for in vitro – in vivo extrapolation of its secretion and renal clearance. The adefovir model was verified with clinical data from nine studies (188 subjects) investigating a range of adefovir intravenous and adefovir‐dipivoxil oral doses in White, Japanese, and Chinese populations with healthy renal function. A previously verified probenecid model, incorporating in vivo OAT1/3 inhibitory constant estimated using OAT1/3 endogenous biomarker (4‐pyridoxic acid) clinical data, was utilized. The ratio of adefovir maximal plasma concentrations (C max R) and area under the curve (AUCR) after mid‐to‐high single oral doses of probenecid was predicted within the stringent Guest criterion. With the lowest probenecid dose (0.5 g), adefovir AUCR and C max R were slightly overpredicted but still within a 1.5‐fold error. Application of the adefovir model to patients with severe chronic kidney disease (CKD) accounted for our previously recommended additional 50% decrease in OAT1 activity beyond the decline of glomerular filtration rate. The model successfully predicted 3‐fold higher adefovir C max and 6‐fold higher AUC in patients with severe CKD relative to healthy individuals. This study reinforces the role of PBPK modeling to predict transporter‐mediated DDI (coupled with biomarker‐informed approach to optimize in vivo inhibitory constant) and the effect of renal impairment on OAT1/3 drugs in lieu of clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
- Certara Predictive Technologies, Sheffield, UK.
ORCID-Profile: Shawn Pei Feng Tan, Amin Rostami-Hodjegan, Daniel Scotcher, Aleksandra Galetin
Zitieren
APA
Tan, S. P. F., Wu, H., Rostami-Hodjegan, A., Scotcher, D., & Galetin, A. (2025). Evaluation of Adefovir PBPK Model to Assess Biomarker‐Informed OAT1 Drug–Drug Interaction and Effect of Chronic Kidney Disease. CPT: Pharmacometrics & Systems Pharmacology, 14(5), 964-974. https://doi.org/10.1002/psp4.70010
Vancouver
Tan SPF, Wu H, Rostami-Hodjegan A, Scotcher D, Galetin A. Evaluation of Adefovir PBPK Model to Assess Biomarker‐Informed OAT1 Drug–Drug Interaction and Effect of Chronic Kidney Disease. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(5):964-974. doi:10.1002/psp4.70010
BibTeX
@article{Tan2025,
author = {Tan, Shawn Pei Feng and Wu, Huaying and Rostami-Hodjegan, Amin and Scotcher, Daniel and Galetin, Aleksandra},
title = {Evaluation of Adefovir PBPK Model to Assess Biomarker‐Informed OAT1 Drug–Drug Interaction and Effect of Chronic Kidney Disease},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {5},
pages = {964--974},
doi = {10.1002/psp4.70010}
}
EUVIMED